Endoglin Cancer Research Results

Endoglin, CD105: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Endoglin, also known as CD105, is a glycoprotein that is primarily expressed on the surface of endothelial cells and is involved in angiogenesis, the process of new blood vessel formation. Elevated levels of endoglin have been associated with poor prognosis in various cancers, including breast, colorectal, and lung cancers. Its expression levels may serve as a biomarker for tumor progression and response to therapy.

Many solid tumors such as breast, lung, colon, and pancreatic cancers exhibit high CD105 expression in their peritumoral and intratumoral vasculature. This is often used as a surrogate marker for the extent of angiogenesis.

CD105 (endoglin) is a pivotal protein in the regulation of angiogenesis. In cancer, its high expression—especially on the endothelial cells of tumor vasculature—is often associated with increased angiogenic activity, aggressive tumor behavior, and poorer prognosis.
Scientific Papers found: Click to Expand⟱
419- Api,    Apigenin inhibited hypoxia induced stem cell marker expression in a head and neck squamous cell carcinoma cell line
- in-vitro, SCC, HN30 - in-vitro, SCC, HN8
CD44↓,
Nanog↓,
Endoglin↓, CD105
VEGF↓,
CSCs↓, Apigenin reduces the number of cells expressing stem cell markers under hypoxia.

7991- itraC,    A Phase II Trial of Perioperative Oral Itraconazole for the Management of Low-Risk Basal Cell Carcinoma
- Trial, BCC, NA
Smo↓, Itraconazole has demonstrated clinical activity in such cases by blocking the smoothened (SMO) receptor.
Dose↓, Patients received itraconazole tablets 200 mg twice daily for 60 days before resection.
TumVol↓, median tumour diameter before treatment was 14 mm (IQR 11–16 mm), and after treatment, 13 mm (IQR 11–15 mm), and this reduction in tumour size was statistically significant
Endoglin↓, decrease in the expression of CD105, an endothelial marker (p < 0.0001), was observed
angioG↓, with a decrease in tumour angiogenesis and a favourable safety profile.
toxicity↝,
GLI3↓, there appears to be a trend suggesting that Itraconazole treatment may reduce GLI3 expression (from 0.71 [0.03–9.17] to 0.33 [
toxicity↓, observe that the use of itraconazole was safe, as no changes were observed during or after treatment. Such results are expected, as the safety of itraconazole is already well known


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD44↓, 1,   CSCs↓, 1,   Nanog↓, 1,   Smo↓, 1,  

Migration(tgid=13) ⓘ

GLI3↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   Endoglin↓, 2,   VEGF↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↓, 1,  

Functional Outcomes(tgid=23) ⓘ

toxicity↓, 1,   toxicity↝, 1,   TumVol↓, 1,  
Total Targets: 12

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Endoglin, CD105
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:97  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page